Transforming the treatment journey for patients with early-stage EGFR-mutated NSCLC

At a symposium hosted by AstraZeneca on 20 April 2023, a panel of distinguished experts discussed the latest developments in the management of early-stage epidermal growth factor receptor (EGFR)–mutated (EGFRm) non–small–cell lung cancer (NSCLC). Speakers included Dr Vincent Ng, who highlighted the advances in surgical interventions, and Professor Masahiro Tsuboi, who addressed unmet clinical needs in early-stage EGFRm NSCLC and potential solutions such as osimertinib as an adjuvant treatment. The symposium featured a lively debate on the utility of disease-free survival (DFS) as a surrogate endpoint and concluded with an informative panel discussion.